Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Dec 29, 2023 (3 years ago)

Ibuprofen and Famotidine Tablets 800mg/26.6mg

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Foreign Tablet/Capsule: A stray Rasagiline Mesylate 1 mg tablet was discovered in an unopened bottle of Ibuprofen and Famotidine.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Ibuprofen and Famotidine Tablets 800mg/26.6mg, Rx Only, 90 Tablets per Bottle, manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC., Parsippany, NJ 07054, NDC 67877-626-90

Affected NDC 67877-0626-90

Compare with the code on your package — it is the most precise check available.

Drug: Ibuprofen Category: Pain Relief & OTC Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Ibuprofen and famotidine
NDC 67877-0626
IBUPROFEN 800 mg/1; FAMOTIDINE 26.6 mg/1 Tablet, Film Coated
Oral
Ascend Laboratories, LLC Rx
Recalling firm
Ascend Laboratories, LLC
NDC code
67877-626-90
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0237-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Ibuprofen recalls

See all
Class II · Moderate risk

Advil a) Ibuprofen

CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.

Ongoing cGMP deviation Gold Star Distribution INC D-0261-2026
Class III · Low risk

IBU (ibuprofen)

Failed Tablet/Capsule Specifications

Ongoing Failed specification Dr. Reddy's Laboratories, Inc. NDC 55111-683-05 D-0047-2025
Class II · Moderate risk

Ibuprofen 800mg

Failed Impurities/Degradation Specifications: Product failed impurity specifications at the 18-month stability testing.

Ongoing Impurity / degradation Direct Rx NDC 61919-0621-15 D-0041-2025

Other recalls by Ascend Laboratories, LLC

All 2023 recalls
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7253-04 D-0739-2026
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7253-68 D-0738-2026
Class III · Low risk

Dabigatran Etexilate Capsules

Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 0904-7255-68 D-0737-2026